iHuman released FY2024 annual earnings on March 25 (EST), actual revenue 128.09 M USD (forecast 164.79 M USD), actual EPS 0.25 USD

Brief Summary

iHuman reported its 2024 fiscal year earnings with a revenue of $128.09 million and an EPS of $0.25, which was below the expected revenue of $165 million, indicating a miss in market expectations.

Impact of The News

Financial Indicators

• Earnings Per Share (EPS): iHuman’s EPS stands at $0.25, meeting the expected EPS but falling short on revenue expectations compared to forecasts.
• Revenue: The company reported a revenue of $128.09 million, which is below the expected $165 million, indicating a significant shortfall in achieving anticipated financial targets.

Market Position

• Comparison with Peers: Other companies, such as 思摩尔国际， showed revenue growth with 思摩尔国际’s revenue increasing by 5.31% to 117.99 billion yuan, and its self-owned brand sales growing by 34.0% . Meanwhile, 药明康德’s revenue grew by 5.2% after adjusting for external factors, and 思摩尔国际 also showed strong growth in specific segments . In contrast, iHuman’s revenue performance indicates it is trailing behind some of its peers in terms of growth rates.

Business Status and Transmission Mechanism

• Revenue Miss: The significant miss on revenue expectations could signal underlying challenges in market penetration or product sales effectiveness.
• Subsequent Trends: Given the revenue shortfall, iHuman may need to reassess its market strategies or products to align future performance with expectations. This financial result could influence investor sentiment and affect stock performance in the short term. Additionally, strategic shifts towards innovation or expanded market reach could be expected as a response to the financial outcomes.